Adma Biologics reported $665.18M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Adma Biologics USD 665.18M 40.94M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Novavax USD 1.04B 133.35M Mar/2026
Omeros USD 200.57M 34.59M Jun/2025
Takeda JPY 15.45T 44.34B Mar/2026